Indefinite Delivery Contract HHSN271201400013I

The multiple award IDV was issued by the National Cancer Institute, within the Department of Health and Human Services' National Institutes of Health, to provide analysis and synthesis of GMP and non-GMP bulk drugs and pharmaceutical formulations. Mriglobal, doing business as Midwest Research Institute, was awarded the IDV with a potential value of $12.1M and a period of performance through April 2028. The IDV facilitates the placement of task orders for preclinical and clinical development...

This Indefinite Delivery Contract (IDC) was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to PPD Development LP, a global contract research organization (CRO). The contract has a total potential value of $3,912,150 and provides comprehensive, integrated drug development, laboratory, and lifecycle management services to support NCATS' bioanalytical method development programs. This...

The National Institutes of Health National Center for Advancing Translational Sciences awarded multiple indefinite delivery contracts to support its drug development programs. The IDVs have a potential value of $19.4 million and a period of performance through June 2027. CCS Associates, Inc. received task orders against its IDV to provide regulatory support services. A $115,581 order involves preparing a Pre-Investigational New Drug Application for clinical development of mitragynine. A $242,355...

Societal Cdmo San Diego, LLC, a small disadvantaged business and subsidiary of Irisys, Inc., was awarded an Indefinite Delivery Contract by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued up to $6 million, is for the SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL services to support the NCI's cancer research and drug development programs. Under this Indefinite Delivery Contract,...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to R T I International to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product development...

This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The $49.9 million, multiple-award IDC will provide Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products from August 2024 through July 2031. The contract aims to obtain a broad range of preclinical services...

The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...

The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...

This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...

This Indefinite Delivery Contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the non-profit research and development institute Sri International. The $9,750,000 IDC covers a 5-year period from September 12, 2023 to September 11, 2028, and is for Toxicological Evaluations of Potential Medications to support NIDA's mission. Under this IDC, Sri International has been awarded two task orders to date. The first...